Cargando…
Glucose Metabolism Reprogramming of Primary Tumor and the Liver Is Associated With Disease-Free Survival in Patients With Early NSCLC
PURPOSE: Tumor promote disease progression by reprogramming their metabolism and that of distal organs, so it is of great clinical significance to study the changes in glucose metabolism at different tumor stages and their effect on glucose metabolism in other organs. METHODS: A retrospective single...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581354/ https://www.ncbi.nlm.nih.gov/pubmed/34778067 http://dx.doi.org/10.3389/fonc.2021.752036 |
_version_ | 1784596789502935040 |
---|---|
author | Tan, Hongpei Ma, Mengtian Huang, Jing Zhu, Wenhao Hu, Shuo Zheng, Kai Rong, Pengfei |
author_facet | Tan, Hongpei Ma, Mengtian Huang, Jing Zhu, Wenhao Hu, Shuo Zheng, Kai Rong, Pengfei |
author_sort | Tan, Hongpei |
collection | PubMed |
description | PURPOSE: Tumor promote disease progression by reprogramming their metabolism and that of distal organs, so it is of great clinical significance to study the changes in glucose metabolism at different tumor stages and their effect on glucose metabolism in other organs. METHODS: A retrospective single-centre study was conducted on 253 NSCLC (non-small cell lung cancer) patients with negative lymph nodes and no distant metastasis. According to the AJCC criteria, the patients were divided into different groups based on tumor size: stage IA, less than 3 cm (group 1, n = 121); stage IB, greater than 3-4 cm (group 2, n = 64); stage IIA, greater than 4-5 cm (group 3, n = 36); and stage IIB, greater than 5-7 cm (group 4, n = 32). All of the patients underwent baseline (18)F-FDG PET/CT scans, and the primary lesion SUVmax (maximum standardized uptake value), liver SUVmean (mean standardized uptake value), spleen SUVmean, TLR (Tumor-to-liver SUV ratio) and TSR (Tumor-to-spleen SUV ratio) were included in the study, combined with clinical examination indicators to evaluate DFS (disease free survival). RESULTS: In NSCLC patients, with the increase in the maximum diameter of the tumor, the SUVmax of the primary lesion gradually increased, and the SUVmean of the liver gradually decreased. The primary lesion SUVmax, liver SUVmean, TLR and TSR were related to disease recurrence or death. The best predictive parameters were different when the tumor size differed. SUVmax had the highest efficiency when the tumor size was less than 4 cm (AUC:0.707 (95% CI, 0.430-0.984) tumor size < 3 cm), (AUC:0.726 (95% CI, 0.539-0.912) tumor size 3-4 cm), liver SUVmean had the highest efficiency when the tumor size was 4-5 cm (AUC:0.712 (95% CI, 0.535-0.889)), and TLR had the highest efficiency when the tumor size was 5-7 cm [AUC:0.925 (95%CI, 0.820-1.000)]. CONCLUSIONS: In patients with early NSCLC, glucose metabolism reprogramming occurs in the primary lesion and liver. With the increase in tumor size, different metabolic parameters should be selected to evaluate the prognosis of patients. |
format | Online Article Text |
id | pubmed-8581354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85813542021-11-12 Glucose Metabolism Reprogramming of Primary Tumor and the Liver Is Associated With Disease-Free Survival in Patients With Early NSCLC Tan, Hongpei Ma, Mengtian Huang, Jing Zhu, Wenhao Hu, Shuo Zheng, Kai Rong, Pengfei Front Oncol Oncology PURPOSE: Tumor promote disease progression by reprogramming their metabolism and that of distal organs, so it is of great clinical significance to study the changes in glucose metabolism at different tumor stages and their effect on glucose metabolism in other organs. METHODS: A retrospective single-centre study was conducted on 253 NSCLC (non-small cell lung cancer) patients with negative lymph nodes and no distant metastasis. According to the AJCC criteria, the patients were divided into different groups based on tumor size: stage IA, less than 3 cm (group 1, n = 121); stage IB, greater than 3-4 cm (group 2, n = 64); stage IIA, greater than 4-5 cm (group 3, n = 36); and stage IIB, greater than 5-7 cm (group 4, n = 32). All of the patients underwent baseline (18)F-FDG PET/CT scans, and the primary lesion SUVmax (maximum standardized uptake value), liver SUVmean (mean standardized uptake value), spleen SUVmean, TLR (Tumor-to-liver SUV ratio) and TSR (Tumor-to-spleen SUV ratio) were included in the study, combined with clinical examination indicators to evaluate DFS (disease free survival). RESULTS: In NSCLC patients, with the increase in the maximum diameter of the tumor, the SUVmax of the primary lesion gradually increased, and the SUVmean of the liver gradually decreased. The primary lesion SUVmax, liver SUVmean, TLR and TSR were related to disease recurrence or death. The best predictive parameters were different when the tumor size differed. SUVmax had the highest efficiency when the tumor size was less than 4 cm (AUC:0.707 (95% CI, 0.430-0.984) tumor size < 3 cm), (AUC:0.726 (95% CI, 0.539-0.912) tumor size 3-4 cm), liver SUVmean had the highest efficiency when the tumor size was 4-5 cm (AUC:0.712 (95% CI, 0.535-0.889)), and TLR had the highest efficiency when the tumor size was 5-7 cm [AUC:0.925 (95%CI, 0.820-1.000)]. CONCLUSIONS: In patients with early NSCLC, glucose metabolism reprogramming occurs in the primary lesion and liver. With the increase in tumor size, different metabolic parameters should be selected to evaluate the prognosis of patients. Frontiers Media S.A. 2021-10-28 /pmc/articles/PMC8581354/ /pubmed/34778067 http://dx.doi.org/10.3389/fonc.2021.752036 Text en Copyright © 2021 Tan, Ma, Huang, Zhu, Hu, Zheng and Rong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Tan, Hongpei Ma, Mengtian Huang, Jing Zhu, Wenhao Hu, Shuo Zheng, Kai Rong, Pengfei Glucose Metabolism Reprogramming of Primary Tumor and the Liver Is Associated With Disease-Free Survival in Patients With Early NSCLC |
title | Glucose Metabolism Reprogramming of Primary Tumor and the Liver Is Associated With Disease-Free Survival in Patients With Early NSCLC |
title_full | Glucose Metabolism Reprogramming of Primary Tumor and the Liver Is Associated With Disease-Free Survival in Patients With Early NSCLC |
title_fullStr | Glucose Metabolism Reprogramming of Primary Tumor and the Liver Is Associated With Disease-Free Survival in Patients With Early NSCLC |
title_full_unstemmed | Glucose Metabolism Reprogramming of Primary Tumor and the Liver Is Associated With Disease-Free Survival in Patients With Early NSCLC |
title_short | Glucose Metabolism Reprogramming of Primary Tumor and the Liver Is Associated With Disease-Free Survival in Patients With Early NSCLC |
title_sort | glucose metabolism reprogramming of primary tumor and the liver is associated with disease-free survival in patients with early nsclc |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581354/ https://www.ncbi.nlm.nih.gov/pubmed/34778067 http://dx.doi.org/10.3389/fonc.2021.752036 |
work_keys_str_mv | AT tanhongpei glucosemetabolismreprogrammingofprimarytumorandtheliverisassociatedwithdiseasefreesurvivalinpatientswithearlynsclc AT mamengtian glucosemetabolismreprogrammingofprimarytumorandtheliverisassociatedwithdiseasefreesurvivalinpatientswithearlynsclc AT huangjing glucosemetabolismreprogrammingofprimarytumorandtheliverisassociatedwithdiseasefreesurvivalinpatientswithearlynsclc AT zhuwenhao glucosemetabolismreprogrammingofprimarytumorandtheliverisassociatedwithdiseasefreesurvivalinpatientswithearlynsclc AT hushuo glucosemetabolismreprogrammingofprimarytumorandtheliverisassociatedwithdiseasefreesurvivalinpatientswithearlynsclc AT zhengkai glucosemetabolismreprogrammingofprimarytumorandtheliverisassociatedwithdiseasefreesurvivalinpatientswithearlynsclc AT rongpengfei glucosemetabolismreprogrammingofprimarytumorandtheliverisassociatedwithdiseasefreesurvivalinpatientswithearlynsclc |